采用深度测序技术从循环肿瘤 DNA 检测多发性骨髓瘤微小残留病灶与骨髓检测结果不相关。
Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow.
机构信息
Institut Universitaire du Cancer-Oncopole and Centre de Recherches en Cancérologie de Toulouse INSERM U1037, Toulouse, France.
Hematology Department, University Hospital, Nancy, France.
出版信息
Blood Adv. 2018 Nov 13;2(21):2811-2813. doi: 10.1182/bloodadvances.2018025197.
Abstract
There is no correlation between ctDNA and bone marrow for MRD by NGS using only immunoglobulin gene rearrangements in myeloma patients.
摘要
在多发性骨髓瘤患者中，仅使用免疫球蛋白基因重排的 NGS 检测 ctDNA 与骨髓 MRD 之间没有相关性。
相似文献
1
Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow.采用深度测序技术从循环肿瘤 DNA 检测多发性骨髓瘤微小残留病灶与骨髓检测结果不相关。
Blood Adv. 2018 Nov 13;2(21):2811-2813. doi: 10.1182/bloodadvances.2018025197.
2
Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.深度测序显示，大多数多发性骨髓瘤患者的外周血中存在骨髓瘤细胞。
Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):131-139.e1. doi: 10.1016/j.clml.2013.09.013. Epub 2013 Oct 2.
3
Monitoring minimal residual disease in the bone marrow using next generation sequencing.利用下一代测序技术监测骨髓中的微小残留病灶。
Best Pract Res Clin Haematol. 2020 Mar;33(1):101149. doi: 10.1016/j.beha.2020.101149. Epub 2020 Jan 17.
4
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.微小残留病灶检测在多发性骨髓瘤治疗选择和药物研发中的作用：当前价值与未来应用。
Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.
5
Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA.通过对循环骨髓瘤细胞和游离骨髓瘤DNA的V(D)J重排进行二代测序来监测多发性骨髓瘤。
Haematologica. 2017 Jun;102(6):1105-1111. doi: 10.3324/haematol.2016.161414. Epub 2017 Feb 9.
6
Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple Myeloma.循环肿瘤 DNA 检测多发性骨髓瘤微小残留病。
Semin Hematol. 2018 Jan;55(1):38-40. doi: 10.1053/j.seminhematol.2018.03.002. Epub 2018 Mar 7.
7
Tracking myeloma tumor DNA in peripheral blood.外周血中骨髓瘤肿瘤 DNA 的检测。
Best Pract Res Clin Haematol. 2020 Mar;33(1):101146. doi: 10.1016/j.beha.2020.101146. Epub 2020 Jan 14.
8
MRD Assessment in Multiple Myeloma: Progress and Challenges.多发性骨髓瘤中的微小残留病灶评估：进展与挑战。
Curr Hematol Malig Rep. 2021 Apr;16(2):162-171. doi: 10.1007/s11899-021-00633-5. Epub 2021 May 5.
9
Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.循环肿瘤 DNA 序列分析可替代多发性骨髓瘤骨髓穿刺。
Nat Commun. 2017 May 11;8:15086. doi: 10.1038/ncomms15086.
10
Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias.循环肿瘤DNA作为浆细胞异常增殖性疾病的液体活检
Haematologica. 2018 Jun;103(6):e245-e248. doi: 10.3324/haematol.2017.184358. Epub 2018 Feb 22.
引用本文的文献
1
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy.将微小残留病阴性作为多发性骨髓瘤治疗的主要目标。
Drugs. 2025 Sep 4. doi: 10.1007/s40265-025-02232-7.
2
Measurable residual disease in hematologic malignancies: a biomarker in search of a standard.血液系统恶性肿瘤中的可测量残留病：寻求标准的生物标志物。
EClinicalMedicine. 2025 Jul 10;86:103348. doi: 10.1016/j.eclinm.2025.103348. eCollection 2025 Aug.
3
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma.多发性骨髓瘤临床管理中微小残留病评估的机遇与挑战
Nat Rev Clin Oncol. 2025 Apr 7. doi: 10.1038/s41571-025-01017-x.
4
Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.解读多发性骨髓瘤中嵌合抗原受体T细胞治疗后循环肿瘤DNA的反应动态及治疗耐药性
Nat Commun. 2025 Feb 20;16(1):1824. doi: 10.1038/s41467-025-56486-6.
5
Loss of Heterozygosity and Mutations in the RAS-ERK Pathway Genes in Tumor Cells of Various Loci in Multiple Myeloma.多发性骨髓瘤中不同部位肿瘤细胞中 RAS-ERK 通路基因的杂合性丢失和突变。
Int J Mol Sci. 2024 Aug 30;25(17):9426. doi: 10.3390/ijms25179426.
6
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.通过质谱法检测外周血残留病的单点及动力学情况以预测GEM-CESAR试验中高危冒烟型多发性骨髓瘤患者的预后
Haematologica. 2024 Dec 1;109(12):4056-4066. doi: 10.3324/haematol.2024.285742.
7
[Minimal residual disease assessment and progress in multiple myeloma].[多发性骨髓瘤的微小残留病评估与进展]
Zhonghua Xue Ye Xue Za Zhi. 2024 Feb 14;45(2):203-208. doi: 10.3760/cma.j.cn121090-20230728-00036.
8
Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant.未计划进行前期移植的多发性骨髓瘤患者循环肿瘤浆细胞及外周血可测量残留病评估
Hemasphere. 2024 Apr 1;8(4):e63. doi: 10.1002/hem3.63. eCollection 2024 Apr.
9
Role of minimal residual disease assessment in multiple myeloma.微小残留病灶评估在多发性骨髓瘤中的作用。
Haematologica. 2024 Jul 1;109(7):2049-2059. doi: 10.3324/haematol.2023.284662.
10
Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future.多发性骨髓瘤中的微小残留病：过去、现在与未来
Cancers (Basel). 2023 Jul 20;15(14):3687. doi: 10.3390/cancers15143687.
本文引用的文献
1
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.深度测序检测微小残留病灶阴性是多发性骨髓瘤的一个主要预后因素。
Blood. 2018 Dec 6;132(23):2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24.
2
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.通过游离DNA测序对多发性骨髓瘤进行基因组发现与克隆追踪
Leukemia. 2018 Aug;32(8):1838-1841. doi: 10.1038/s41375-018-0115-z. Epub 2018 Mar 27.
3
Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.循环肿瘤 DNA 序列分析可替代多发性骨髓瘤骨髓穿刺。
Nat Commun. 2017 May 11;8:15086. doi: 10.1038/ncomms15086.
4
Liquid biopsies come of age: towards implementation of circulating tumour DNA.液体活检时代的到来：迈向循环肿瘤 DNA 的临床应用。
Nat Rev Cancer. 2017 Apr;17(4):223-238. doi: 10.1038/nrc.2017.7. Epub 2017 Feb 24.
5
Liquid Biopsies, What We Do Not Know (Yet).液体活检，未解之谜。
Cancer Cell. 2017 Feb 13;31(2):172-179. doi: 10.1016/j.ccell.2017.01.002.
6
Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA.通过对循环骨髓瘤细胞和游离骨髓瘤DNA的V(D)J重排进行二代测序来监测多发性骨髓瘤。
Haematologica. 2017 Jun;102(6):1105-1111. doi: 10.3324/haematol.2016.161414. Epub 2017 Feb 9.
7
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.用于高灵敏度和标准化检测多发性骨髓瘤微小残留病的新一代流式检测技术。
Leukemia. 2017 Oct;31(10):2094-2103. doi: 10.1038/leu.2017.29. Epub 2017 Jan 20.
8
Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.循环肿瘤 DNA 分析显示空间突变异质性与骨髓瘤疾病复发一致。
Leukemia. 2017 Aug;31(8):1695-1705. doi: 10.1038/leu.2016.366. Epub 2016 Nov 30.
9
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
10
Circulating cell-free DNA in hematological malignancies.血液系统恶性肿瘤中的循环游离DNA
Haematologica. 2016 Sep;101(9):997-9. doi: 10.3324/haematol.2015.131128.
Zotero 插件